Key Points
- Takeda insider Giles Platford sold 55,617 shares for $1.16 million at an average price of $20.90, reducing his stake by 17.07% to 270,253 shares.
- Takeda shares opened at $21.23 and were up 0.8%; the stock was near its 12-month high of $21.73.
- Analyst sentiment is positive: MarketBeat reports an average Buy rating, with one Strong Buy, two Buy, and one Hold rating.
Takeda Pharmaceutical Co. (NYSE:TAK - Get Free Report) insider Giles Platford sold 55,617 shares of the firm's stock in a transaction that occurred on Wednesday, November 4th. The shares were sold at an average price of $20.90, for a total value of $1,162,395.30. Following the completion of the sale, the insider directly owned 270,253 shares in the company, valued at $5,648,287.70. This trade represents a 17.07% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Giles Richard Platford also recently made the following trade(s):
- On Monday, August 10th, Giles Platford sold 31,083 shares of Takeda Pharmaceutical stock. The stock was sold at an average price of $17.10, for a total value of $531,519.30.
Takeda Pharmaceutical Stock Up 0.8%
Shares of TAK stock opened at $21.23 on Friday. Takeda Pharmaceutical Co. has a 12 month low of $13.56 and a 12 month high of $21.73. The company has a quick ratio of 0.60, a current ratio of 1.15 and a debt-to-equity ratio of 0.56. The firm has a market cap of $68.05 billion, a PE ratio of 12.03 and a beta of -0.02. The stock has a 50 day moving average of $19.06 and a 200-day moving average of $17.64.
Analyst Ratings Changes
Several equities analysts recently commented on the stock. Weiss Ratings upgraded shares of Takeda Pharmaceutical from a "hold (c)" rating to a "hold (c+)" rating in a research note on Tuesday. Wall Street Zen raised shares of Takeda Pharmaceutical from a "hold" rating to a "buy" rating in a report on Saturday, July 18th. Finally, Zacks Research upgraded shares of Takeda Pharmaceutical from a "hold" rating to a "strong-buy" rating in a research report on Friday, October 30th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, Takeda Pharmaceutical presently has an average rating of "Buy".
Check Out Our Latest Report on Takeda Pharmaceutical
Hedge Funds Weigh In On Takeda Pharmaceutical
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Renaissance Technologies LLC raised its holdings in Takeda Pharmaceutical by 14.2% in the 1st quarter. Renaissance Technologies LLC now owns 2,989,100 shares of the company's stock valued at $55,358,000 after acquiring an additional 370,800 shares in the last quarter. Quantinno Capital Management LP lifted its position in shares of Takeda Pharmaceutical by 20.6% in the 1st quarter. Quantinno Capital Management LP now owns 1,289,326 shares of the company's stock worth $23,878,000 after acquiring an additional 219,999 shares during the period. Quadrant Capital Group LLC grew its holdings in shares of Takeda Pharmaceutical by 67.8% during the 3rd quarter. Quadrant Capital Group LLC now owns 136,966 shares of the company's stock worth $2,537,000 after purchasing an additional 55,360 shares in the last quarter. Royal Bank of Canada grew its holdings in shares of Takeda Pharmaceutical by 11.0% during the 1st quarter. Royal Bank of Canada now owns 614,851 shares of the company's stock worth $11,386,000 after purchasing an additional 60,725 shares in the last quarter. Finally, Bleakley Financial Group LLC increased its position in shares of Takeda Pharmaceutical by 19.0% during the first quarter. Bleakley Financial Group LLC now owns 431,602 shares of the company's stock valued at $7,993,000 after purchasing an additional 68,844 shares during the period. 9.17% of the stock is currently owned by institutional investors.
About Takeda Pharmaceutical
(
Get Free Report)
Takeda Pharmaceutical Company Limited is a global biopharmaceutical company headquartered in Tokyo, Japan. The company researches, develops, manufactures and commercializes medicines for patients worldwide, with a focus on areas of significant unmet medical need. Its principal therapeutic areas include gastroenterology, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines.
Takeda's portfolio includes treatments such as Entyvio for inflammatory bowel disease, Takhzyro for hereditary angioedema, and medicines for certain blood cancers and rare conditions.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
